AXA IM and BNPP AM are progressively merging and streamlining our legal entities to create a unified structure. Whilst this is ongoing, we will continue to operate two seperate websites both branded BNPP AM. Learn more. 

Marie-Christine Bissery

Oncology specialist

Skills and experience

Dr. Marie-Christine Bissery is the Chief Scientific Officer at Cureteq AG. Cureteq is a biotechnology and asset management company developing new innovative medicines based on a sophisticated artificial intelligence (AI) platform. Cureteq leverages AI to identify the optimal applications of a given molecule and to devise optimized and de-risked clinical development plans. Dr. Marie-Christine Bissery has over thirty years of pharmaceutical, biotech, and academic experience in preclinical and early clinical research with a main focus in oncology. She spent ten years in Biotech as CSO and CDO at Genticel and Novintum. She is also a Research and Development Advisor for Oncology Biotechs and Investment Funds.

Education

Dr. Marie-Christine Bissery holds a PhD, and Master’s degree in Pharmaceutical Sciences and a Doctorate in Pharmacy from University of Paris XI, France. She is also extensively published and patented.

    AXA IM and BNPP AM are progressively merging

    AXA IM and BNPP AM are progressively merging and streamlining our legal entities to create a unified structure

    AXA Investment Managers joined BNP Paribas Group in July 2025. Following the merger of AXA Investment Managers Paris and BNP PARIBAS ASSET MANAGEMENT Europe and their respective holding companies on December 31, 2025, the combined company now operates under the BNP PARIBAS ASSET MANAGEMENT Europe name.